Welsh NHS recommends saxagliptin as an option in type 2 diabetes

The All Wales Medicines Strategy Group has published a recommendation regarding saxagliptin, the DPP-4 inhibitor (Onglyza®)

Saxagliptin is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control.

This advice is based on:

  1. An appraisal of evidence submitted in an assessment report, and
  2. A response submitted by the manufacturer
  3. Clinical expert opinion
  4. Patient and carer input.


The full text can be accessed from the link below:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2012:  Saxagliptin (Onglyza®), July 2012

The assessment report underpinning this recommendation is:

AWMSG Secretariat Assessment Report – Advice No. 2012: Saxagliptin (Onglyza®), June 2012

A summary of the clinical expert opinion is also available online.

Read more about DPP-4 inhibitors on The Diabetes Elf.

Share this post: Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+ Share via email


I am an information scientist with an interest in making knowledge from systematic research more accessible to people who need it. This means you. I've been attempting this in the area of Evidence-Based Health Care since 1995. So far the results have been mixed. For some reason we expected busy clinicians to search databases and appraise papers instead of seeing patients. We also expected publishers to make the research freely available to the people who paid for it.. Ha! Hence The National Elf service.

More posts - Website

Follow me here –